{"id":"W3082708938","doi":"10.2217/fon-2020-0586","title":"Avelumab and Axitinib Combination Therapy for the Treatment of Advanced Renal Cell Carcinoma","year":2020,"lang":"en","type":"review","venue":"Future Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Pfizer","keywords":"Nivolumab; Axitinib; Avelumab; Medicine; Ipilimumab; Renal cell carcinoma; Oncology; Internal medicine; Immunotherapy; Combination therapy; Cabozantinib; Tyrosine-kinase inhibitor; Targeted therapy; Sunitinib; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024395,0.0004701418,0.0008431677,0.001481749,0.0001616073,0.0004469048,0.0004500733,0.0004383628,0.003903308],"category_scores_gemma":[0.0002718878,0.0001411768,0.0005596475,0.001183877,0.000145856,0.0004871271,0.0003266951,0.0009212703,0.001144616],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003006602,"about_ca_system_score_gemma":0.0004853716,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007850496,"about_ca_topic_score_gemma":0.002454952,"domain_scores_codex":[0.9999013,0.0000191808,0.00001520354,0.00001624837,0.00003921072,0.000008831222],"domain_scores_gemma":[0.9999267,0.00003173678,0.00001727486,0.000001849919,0.00001604789,0.000006382375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001024467,0.00007491658,0.0001180151,0.01933827,0.0002118015,0.0001489907,0.00003620218,0.0003085608,0.001726827,0.001356531,0.01889925,0.9576781],"study_design_scores_gemma":[0.00007797754,0.0002363346,0.001210303,0.005052777,0.0004347959,0.001764299,0.00004382838,0.0001691462,0.0006960364,0.0009548676,0.9893414,0.00001822973],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002446042,0.9985023,0.00007474456,0.0001059882,0.00008154131,0.000006951061,0.00002475362,0.00000588363,0.0009533613],"genre_scores_gemma":[0.001257268,0.997775,0.0001233483,0.000130988,0.00006210966,0.000007468026,0.00004606557,0.000001030115,0.0005966043],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003903308,"threshold_uncertainty_score":0.01305783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04777237359308242,"score_gpt":0.3457187380641106,"score_spread":0.2979463644710282,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}